Advances in the pharmacologic management of early Parkinson disease

Neurologist

Volumn 13, Issue 3, 2007, Pages 126-132

  Hauser, Robert A ^b,c,d   Zesiewicz, Theresa A ^a,b,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Pharmacology and Experimental Therapeutics   (United States)

^d National Parkinson Foundation Center of Excellence   (United States)

Author keywords

COMT inhibitors; Dopamine agonists; Levodopa; Monoamine oxidase type B inhibitors; Parkinson disease; Treatment

Indexed keywords

AMANTADINE; AMPHETAMINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOCOPHEROL; TOLCAPONE;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DYSKINESIA; EDEMA; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; INFECTION; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION;

ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PARKINSON DISEASE;

EID: 34248374207     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000256433.15481.eb     Document Type: Review

References (52)

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 suppl 5):S1-S88.
3. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain. 2000;123(pt 11):2297-2305.
4. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
5. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
6. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677-687.
7. Reynolds GP, Riederer P, Rausch WD. Dopamine metabolism in human brain: effects of monoamine oxidase inhibition in vitro by (-) deprenyl and (+) and (-) tranylcypromine. J Neural Transm. 1980;16:173-178.
8. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand. 1983;95:57-80.
9. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
10. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.
11. Chrisp P, Mammen GJ, Sorkin EM. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991;1:228-248.
12. Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:228-234.
13. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem. 1997;68:33-39.
14. Tatton WG, Ju WY, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem. 1994;63:1572-1575.
15. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996;47(6 suppl 3):S171-183.
16. Carlile GW, Chalmers-Redman RME, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol. 2000;57:2-12.
17. Abu-Raya S, Tabakman R, Blaugrund E, et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116.
18. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
19. Huang W, Chen Y, Shohami E, et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
20. Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463.
21. Heikkila RE, Duvoisin RC, Finberg JP, et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116:313-317.
22. Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci. 2001;939:320-329.
23. Maruyama W, Takahashi T, Youdim M, et al. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109:467-481.
24. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675-682.
25. Maruyama W, Akao Y, Youdim MBH, et al. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)-and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl. 2000;60:171-186.
26. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
27. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
28. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18:389-396.
29. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
30. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
31. Rascol O, Brooks DJ, Korczyn AD, et al, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
32. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998;21:141-151.
33. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel opamine agonist, as monotherapy in mild to moderate Parkinson's disease: the Pramipexole Study Group. Neurology. 1997;49:724-728.
34. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
35. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005;20:602-610.
36. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
37. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997;49(suppl 1):S58-62.
38. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234-241.
39. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997;49:393-399.
40. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease: Ropinirole Study Group. Neurology. 1998;51:1057-1062.
41. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101.
42. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91-104.
43. Crosby N, Deane KHO, Clarke CE. Amantadine in Parkinson's disease (Cochrane review). Cochrane Database Syst Rev. 2003;(2):CD003467.
44. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease: a double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 1975;25:603-606.
45. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56:1383-1386.
46. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44:913-919.
47. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
48. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 1998;51:1309-1314.
49. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62(suppl 1):S64-S71.
50. Olanow CW. Tolcapone and hepatotoxic effects: Tasmar Advisory Panel. Arch Neurol. 2000;57:263-267.
51. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord. 2005;20:306-314.
52. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. Ann Neurol. 2002;51:604-612.